Eli Lilly Looking to Remove Obstacles to GLP-1 Drugs With Direct Sales -- Market Talk

Dow Jones

2025/10/31

1329 ET - Eli Lilly's direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call. "There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system," Lily USA President Ilya Yuffa says. "We're seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct." The company also said this week patients would be able to pick up Zepbound vials at Walmart. That accessibility is "an important element for us to expand the ability for patients to get treated," Yuffa says. (nicholas.miller@wsj.com)

(END) Dow Jones Newswires

October 30, 2025 13:29 ET (17:29 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579120222"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579120222\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579120222?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 01:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579120222","market":"fut","top_or_hot":-1,"title":"Eli Lilly Looking to Remove Obstacles to GLP-1 Drugs With Direct Sales -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1329 ET - Eli Lilly's direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call. \"There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system,\" Lily USA President Ilya Yuffa says. \"We're seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct.\" The company also said this week patients would be able to pick up Zepbound vials at Walmart. That accessibility is \"an important element for us to expand the ability for patients to get treated,\" Yuffa says. (nicholas.miller@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 13:29 ET (17:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Looking to Remove Obstacles to GLP-1 Drugs With Direct Sales -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Looking to Remove Obstacles to GLP-1 Drugs With Direct Sales -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-31 01:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1329 ET - Eli Lilly's direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call. \"There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system,\" Lily USA President Ilya Yuffa says. \"We're seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct.\" The company also said this week patients would be able to pick up Zepbound vials at Walmart. That accessibility is \"an important element for us to expand the ability for patients to get treated,\" Yuffa says. (nicholas.miller@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 13:29 ET (17:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579120222","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579120222","pubTimestamp":1761845340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1329 ET - Eli Lilly's direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call. \"There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system,\" Lily USA President Ilya Yuffa says. \"We're seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct.\" The company also said this week patients would be able to pick up Zepbound vials at Walmart. That accessibility is \"an important element for us to expand the ability for patients to get treated,\" Yuffa says. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来","GLP":"Global Partners Lp"},"translate_title":"礼来公司希望通过直销消除GLP-1药物的障碍——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1.5,"LLY":1.5},"content_text":"1329 ET - Eli Lilly's direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call. \"There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system,\" Lily USA President Ilya Yuffa says. \"We're seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct.\" The company also said this week patients would be able to pick up Zepbound vials at Walmart. That accessibility is \"an important element for us to expand the ability for patients to get treated,\" Yuffa says. (nicholas.miller@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 13:29 ET (17:29 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}